CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Investing.com -- 4D Molecular Therapeutics (NASDAQ: FDMT) stock rose 36% after the company announced positive 60-week results from its 4D-150 SPECTRA clinical trial in diabetic macular edema (DME) and ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s executive leadership team will host the call, which ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

SINGAPORE (Reuters) -Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major ...

This past year has seen various developments in the field of oncolytic virus therapies - in fundraising and in the clinic.

The MHRA has confirmed major changes to how medical devices are regulated in Great Britain, with new post-market surveillance ...